Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal

Sumitomo Pharma Subsidiary Already Owns 52%

 
• By Mandy Jackson
  
Balance of stones on a blue sky background
Myovant's board established a special committee to weigh Sumitovant's offer and future proposals • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business